Literature DB >> 21951885

Identification of prognostic factors in pancreatic cancer.

Jaime Ruiz-Tovar1, Elena Martín-Pérez, María Encarnación Fernández-Contreras, María Eugenia Reguero-Callejas, Carlos Gamallo-Amat.   

Abstract

BACKGROUND: Surgical resection is the only potentially curative treatment for pancreatic cancer, but it is associated with high complication rates. Outcome is poor, even in those resected cases. Identification of prognostic factors preoperatively may help to improve treatment of these patients, based on the expected response.
METHODS: A retrospective study of clinical variables of 59 patients with histological diagnosis of pancreatic carcinoma at University Hospitals Ramon y Cajal and La Princesa (Madrid, Spain) between 1999 and 2003 was performed.
RESULTS: We analyzed 59 patients (32 males and 27 females) with a mean age of 63.76 years. All patients were operated on, performing palliative surgery in 32% and tumor resection in 68%, including pancreaticoduodenectomy in 51% and distal pancreatectomy in 17%. Median overall survival was 14 months (range: 1-110 months). We observed that the presence of abdominal pain (p = 0.042) and back pain (p = 0.004) at diagnosis, palpation of abdominal mass at physical examination (p = 0.012), preoperative levels of hemoglobin <12 g/dl (p = 0.0006) and serum albumin <2.8 g/dl (p = 0.021), perineural infiltration (p = 0.025), lymph node affection (p = 0.004), stages II, III, and IV (p = 0.001), and presence of residual tumor (R+) (p = 0.008) are all associated with poor survival.
CONCLUSIONS: Abdominal and back pain, palpation of abdominal mass at physical examination, preoperative levels of hemoglobin <12 g/dl and serum albumin <2.8 g/dl, perineural infiltration, lymph node affection, stages II, III, and IV, and the presence of residual tumor are associated with poor outcome.

Entities:  

Mesh:

Year:  2011        PMID: 21951885

Source DB:  PubMed          Journal:  Cir Cir        ISSN: 0009-7411            Impact factor:   0.361


  9 in total

1.  Peripancreatic soft tissue involvement: independent outcome predictor in patients with resected pancreatic adenocarcinoma.

Authors:  Alireza Hamidian Jahromi; Gazi B Zibari; Elnaz Jafarimehr; Quyen Chu; Gregory P Wellman; Runhua Shi; Lester W Johnson; Hosein Shokouh-Amiri
Journal:  Int Surg       Date:  2014 Jan-Feb

2.  Patients with pancreatic adenocarcinoma exhibit elevated levels of myeloid-derived suppressor cells upon progression of disease.

Authors:  Joseph Markowitz; Taylor R Brooks; Megan C Duggan; Bonnie K Paul; Xueliang Pan; Lai Wei; Zachary Abrams; Eric Luedke; Gregory B Lesinski; Bethany Mundy-Bosse; Tanios Bekaii-Saab; William E Carson
Journal:  Cancer Immunol Immunother       Date:  2014-10-11       Impact factor: 6.968

3.  Prognostic Scoring Index for Patients with Metastatic Pancreatic Adenocarcinoma.

Authors:  Hyung Soon Park; Hye Sun Lee; Ji Soo Park; Joon Seong Park; Dong Ki Lee; Se-Joon Lee; Dong Sup Yoon; Min Goo Lee; Hei-Cheul Jeung
Journal:  Cancer Res Treat       Date:  2016-02-03       Impact factor: 4.679

4.  Retrospective cohort of pancreatic and Vater ampullary adenocarcinoma from a reference center in Mexico.

Authors:  Jorge Sánchez-García; Fernando Candanedo-González; Anna Karen Félix-Félix; Damián Sánchez-Ramírez; Rafael Medrano-Guzmán; Miguel Quintana-Quintana; Yair Benjamín Baas-Cabrera; Eugenia Flores-Figueroa
Journal:  Ann Med Surg (Lond)       Date:  2018-04-11

5.  Clinical significance of anemia as a prognostic factor in non-small cell lung cancer carcinoma with activating epidermal growth factor receptor mutations.

Authors:  Hye Seon Kang; Ah Young Shin; Chang Dong Yeo; Chan Kwon Park; Ju Sang Kim; Jin Woo Kim; Seung Joon Kim; Sang Haak Lee; Sung Kyoung Kim
Journal:  J Thorac Dis       Date:  2020-05       Impact factor: 2.895

6.  Systemic Immune-Inflammation Index and Changes of Neutrophil-Lymphocyte Ratio as Prognostic Biomarkers for Patients With Pancreatic Cancer Treated With Immune Checkpoint Blockade.

Authors:  Jin Shang; Xiao Han; Haoran Zha; Haitao Tao; Xiaoyan Li; Fang Yuan; Guangying Chen; Lijie Wang; Junxun Ma; Yi Hu
Journal:  Front Oncol       Date:  2021-02-24       Impact factor: 6.244

7.  Clinical predictors of resectability of pancreatic adenocarcinoma.

Authors:  Majid A Almadi; Othman Alharbi; Nahla Azzam; Mohannad Altayeb; Moammed Javed; Faisal Alsaif; Mazen Hassanain; Abdulsalam Alsharabi; Khalid Al-Saleh; Abdulrahman M Aljebreen
Journal:  Saudi J Gastroenterol       Date:  2013 Nov-Dec       Impact factor: 2.485

8.  Pre-treatment anemia is a poor prognostic factor in soft tissue sarcoma patients.

Authors:  Joanna Szkandera; Armin Gerger; Bernadette Liegl-Atzwanger; Michael Stotz; Hellmut Samonigg; Ferdinand Ploner; Tatjana Stojakovic; Andreas Leithner; Martin Pichler
Journal:  PLoS One       Date:  2014-09-10       Impact factor: 3.240

9.  Prognostic Predicting Role of Contrast-Enhanced Computed Tomography for Locally Advanced Pancreatic Adenocarcinoma.

Authors:  Chien-Shan Cheng; Wei Liu; Liangping Zhou; Wei Tang; Ailing Zhong; Zhiqiang Meng; Lianyu Chen; Zhen Chen
Journal:  Biomed Res Int       Date:  2019-11-26       Impact factor: 3.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.